Justia Antitrust & Trade Regulation Opinion Summaries

Plaintiffs are direct purchasers of traditional blood reagents, used to test blood compatibility between donors and recipients, from Immucor and OrthoClinical (defendants). By 1999, the entire domestic supply of that product was under defendants’ control. In 2000, defendants’ executives attended a trade meeting at which plaintiffs assert the conspiracy began. Defendants soon began rapidly increasing prices. By 2009, many prices had risen more than 2000%. Following a Department of Justice probe, private suits were filed, transferred by the Judicial Panel on Multidistrict Litigation, and consolidated. Plaintiffs sought damages under the Clayton Act, 15 U.S.C. 15, for alleged horizontal price fixing in violation of the Sherman Act, 15 U.S.C. 1. After preliminary approval of plaintiffs’ settlement with Immucor, the court certified plaintiffs’ class of “[a]ll individuals and entities who purchased traditional blood reagents in the United States directly from Defendants ... at any time from January 1, 2000 through the present.” Plaintiffs relied in part on expert testimony to produce their antitrust impact analyses and damages models, which Ortho challenged. The Supreme Court subsequently decided Comcast v. Behrend, which reversed Behrend v. Comcast, on which the district court relied in granting class certification. The Third Circuit vacated, reasoning that the court had no opportunity to consider the implications of Comcast; a court must resolve any Daubert challenges to expert testimony offered to demonstrate conformity with Rule 23 View "In re: Blood Reagents Antitrust Litig." on Justia Law

In 2000, physicians and physician associations imitated a group of class actions against various providers of health plans, which were consolidated into a multidistrict litigation. This appeal involves this complex, twelve-year-old multidistrict litigation, a related multidistrict litigation pending in another federal district, and whether the district court reasonably interpreted the Settlement Agreement in the first action. The court affirmed the Injunction as to plaintiffs' Racketeer Influenced and Corrupt Organizations Act (RICO), 18 U.S.C. 1961, and antitrust claims and as to the Employee Retirement Income Security Act of 1974, 29 U.S.C. 1001 et seq., claims based on the denial or underpayment of benefits following the Settlement Agreement's Effective Date. On remand, the district court will need to determine which of plaintiffs' ERISA claims fall on the permissible side of the line, and reconsider the assessment of sanctions. View "Medical Assoc. of GA, et al. v. Wellpoint, Inc." on Justia Law

Plaintiff sued Defendant, alleging that Defendant aided and abetted Plaintiff’s former attorneys in breaching their fiduciary duties to Plaintiff and that Defendant’s actions violated the Connecticut Unfair Trade Practices Act. The trial court entered summary judgment for Defendant, concluding that Plaintiff’s claims were barred by the applicable three year statutes of limitations and that tolling was inapplicable. The Supreme Court affirmed, holding (1) Plaintiff sufficiently invoked the continuing course of conduct doctrine before the trial court; but (2) equitable tolling pursuant to the continuing course of conduct doctrine was not available under the facts of this case. View "Flannery v. Singer Asset Fin. Co., LLC" on Justia Law